How [14C]-JNT-517 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Male Participants

Study Identifier:
359-201-00003
ClinicalTrials.gov Identifier:
NCT07573449
EudraCT Identifier:
N/A
EU CT ID:
N/A
Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information:
N/A
Study Complete
Subscribe to Updates

Study Details

Medical Condition
  • Healthy Volunteers
Study Drug
  • Drug: [14C]-JNT-517
Date
Jan 2024 - Jan 2025
Phase 1/2
Phase 2/3
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Male
Age: 18 - 55 Years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
  • Inclusion Criteria
  • Body mass index (BMI) between 18.0 to 32.0 kilograms per square meter (kg/m\^2), inclusive.
  • In good health at screening as determined by: a) Medical history, b) Physical examination, c) ECG, d) Clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia \[e.g. suspicion of Gilbert's syndrome based on total and direct bilirubin\] is not acceptable).
  • History of a minimum of 1 bowel movement per day.
  • Able to comprehend and are willing to sign the Informed consent form (ICF) and abide by the study restrictions.
  • Exclusion Criteria
  • Use or intend to use any medications/products known to alter drug absorption, metabolism and excretion processes, including St. John's wort, within 30 days prior to dosing, considered to potentially impact participant safety or the objectives of the study, as determined by the investigator or designee.
  • Alcohol consumption of \>14 units per week.
  • A Positive urine drug screen at screening or positive alcohol test result or positive urine drug screen at check-in.
  • Participants having taken an investigational drug within 30 days prior to screening.
  • Participants who have previously been dosed in \>2 radiolabeled drug studies in the last 12 months.
  • Participants with exposure to significant diagnostic or therapeutic radiation (e.g. serial X-ray, computed tomography scan, barium meal).
  • Previous exposure to JNT-517.
  • Note: Other protocol-specified inclusion/exclusion criteria may apply.

Protocol Summary

The purpose of this study is to determine the absorption, metabolism and excretion of \[14C\]-JNT-517 and to characterize and determine the metabolites present in plasma, urine, and feces in healthy male participants following a single oral administration.

Study Locations

Location
Status
Location
Fortrea Clinical Research Unit Inc.
Madison, Wisconsin, United States, 53704
Status
N/A
© 2025 Otsuka America Pharmaceutical, Inc.
All rights reserved.

July 2025 01US25EUC0279

Requirements information
Inclusion criteria
  • Inclusion Criteria
  • Body mass index (BMI) between 18.0 to 32.0 kilograms per square meter (kg/m\^2), inclusive.
  • In good health at screening as determined by: a) Medical history, b) Physical examination, c) ECG, d) Clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia \[e.g. suspicion of Gilbert's syndrome based on total and direct bilirubin\] is not acceptable).
  • History of a minimum of 1 bowel movement per day.
  • Able to comprehend and are willing to sign the Informed consent form (ICF) and abide by the study restrictions.
  • Exclusion Criteria
  • Use or intend to use any medications/products known to alter drug absorption, metabolism and excretion processes, including St. John's wort, within 30 days prior to dosing, considered to potentially impact participant safety or the objectives of the study, as determined by the investigator or designee.
  • Alcohol consumption of \>14 units per week.
  • A Positive urine drug screen at screening or positive alcohol test result or positive urine drug screen at check-in.
  • Participants having taken an investigational drug within 30 days prior to screening.
  • Participants who have previously been dosed in \>2 radiolabeled drug studies in the last 12 months.
  • Participants with exposure to significant diagnostic or therapeutic radiation (e.g. serial X-ray, computed tomography scan, barium meal).
  • Previous exposure to JNT-517.
  • Note: Other protocol-specified inclusion/exclusion criteria may apply.

We defy limitation,

so that others can too.

Follow Us
OAPI and OPDC Locations

508 Carnegie Center Dr,

Princeton, NJ 08540, United States

Phone 609-524-6788

2440 Research Blvd,

Rockville, MD 20850, United States

Phone 301-424-9055

3956 Point Eden Way

Hayward, CA 94545, United States

Phone 800-562-3974